Is VVUS a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

6,510 people get VVUS articles and Market Currents by email alert.

Get email alerts on VVUS »

HEADLINES:

Vivus Heats Up, Shorts Discouraged On Possible Bidding War
Brian L. Wilson • Fri, May 24 • 7 Comments
Arena - Good Sales, Bad Sales, Long And Short
Spencer Osborne • Fri, May 24 • 25 Comments
First Manhattan Still Playing Hardball With Vivus
Spencer Osborne • Fri, May 24 • 2 Comments
Will Arena's Belviq Be The Next Anti-Obesity Drug To Make The Cover Of Time Magazine?
Reasonable Risk • Thu, May 23 • 23 Comments
VIVUS Announces Scientific Presentations

GlobeNewswire (Wed, 7:00AM)
Arena Pharmaceuticals - Out To Launch Or Out To Lunch?
Spencer Osborne • Wed, May 22 • 40 Comments
The Facebook Effect On Arena's Belviq Sales And Why It Will Ultimately Dwarf Anything Eisai Does
Jacob Smith • Tue, May 21 • 32 Comments
Vivus Taps Into More Cash
Spencer Osborne • Sun, May 19 • 20 Comments
Complete Kyle Bass And Hayman Capital Portfolio Update
Profit Fan • Fri, May 17 • 8 Comments
VIVUS Announces Pricing of Offering of $220 Million of 4.50% Convertible Senior Notes

GlobeNewswire (May 16, 2013)
Vivus - Mild Drama Continues
Spencer Osborne • Wed, May 15 • 24 Comments
VIVUS Announces Proposed Offering of Convertible Senior Notes

GlobeNewswire (May 15, 2013)
VIVUS Announces Scientific Presentations

GlobeNewswire (May 14, 2013)
Vivus Starting To Gain The Advantage Over Arena
Equity Options Guru • Tue, May 14 • 112 Comments
Arena, Vivus, And Off-Label Prescriptions
Spencer Osborne • Tue, May 14 • 100 Comments
VIVUS Mails Letter to Stockholders Providing Business Update

GlobeNewswire (May 13, 2013)
VIVUS Appoints J. Martin Carroll and Jorge Plutzky, M.D. to Board of Directors

GlobeNewswire (May 13, 2013)
Belviq's Sales Will Disappoint: Demographics Matter
EnhydrisPECorp • Fri, May 10 • 297 Comments
Vivus Shifting Gears
Spencer Osborne • Fri, May 10 • 27 Comments
Recent Noteworthy Institutional 5% Ownership Filings In Healthcare Sector
GuruFundPicks • Thu, May 9 • 5 Comments

To learn more about Seeking Alpha Pro, click here.

Vivus Heats Up, Shorts Discouraged On Possible Bidding War
Brian L. Wilson • Fri, May 24 • 7 Comments
First Manhattan Still Playing Hardball With Vivus
Spencer Osborne • Fri, May 24 • 2 Comments
Vivus Taps Into More Cash
Spencer Osborne • Sun, May 19 • 20 Comments
Vivus - Mild Drama Continues
Spencer Osborne • Wed, May 15 • 24 Comments
Arena, Vivus, And Off-Label Prescriptions
Spencer Osborne • Tue, May 14 • 100 Comments
Vivus Shifting Gears
Spencer Osborne • Fri, May 10 • 27 Comments
Arena And Vivus Weaken On Poor Obesity Drug Prospects In Europe
Brian L. Wilson • Tue, May 7 • 18 Comments
Vivus And Anti-Obesity Sector Benefit From New Insurance Deal
Spencer Osborne • Wed, May 1 • 52 Comments
Vivus Gets Positive Development In Europe
Spencer Osborne • Mon, Apr 29 • 1 Comment
Vivus Seeing Traction With Qsymia
Spencer Osborne • Fri, Apr 19 • 59 Comments
Vivus Gets Restrictions Loosened
Spencer Osborne • Wed, Apr 17 • 94 Comments
Vivus May Get Second Wind On Qsymia
Spencer Osborne • Thu, Apr 11 • 89 Comments
Vivus Adds Debt - Avoids Dilution
Spencer Osborne • Wed, Mar 27 • 50 Comments
Is It Time To Buy Vivus?
Efsinvestment • Mon, Mar 25 • 58 Comments
Will Vivus Publish Qsymia Prescription Data?
Spencer Osborne • Tue, Mar 19 • 23 Comments
Is Vivus Under Attack By First Manhattan Co.?
Spencer Osborne • Mon, Mar 11 • 52 Comments
Is Vivus' Run-Up Long Term?
Spencer Osborne • Thu, Mar 7 • 37 Comments
Vivus Changes Qsymia Price Again - What Investors Need To Know
Spencer Osborne • Wed, Mar 6 • 37 Comments
It's Now Time For Vivus Investors To Watch Arena Numbers
Spencer Osborne • Thu, Feb 28 • 60 Comments
Vivus Offers Q4 Results - Qsymia Gaining Traction
Spencer Osborne • Tue, Feb 26 • 25 Comments

Arena - Good Sales, Bad Sales, Long And Short
Spencer Osborne • Fri, May 24 • 25 Comments
Will Arena's Belviq Be The Next Anti-Obesity Drug To Make The Cover Of Time Magazine?
Reasonable Risk • Thu, May 23 • 23 Comments
Arena Pharmaceuticals - Out To Launch Or Out To Lunch?
Spencer Osborne • Wed, May 22 • 40 Comments
The Facebook Effect On Arena's Belviq Sales And Why It Will Ultimately Dwarf Anything Eisai Does
Jacob Smith • Tue, May 21 • 32 Comments
Complete Kyle Bass And Hayman Capital Portfolio Update
Profit Fan • Fri, May 17 • 8 Comments
Vivus Starting To Gain The Advantage Over Arena
Equity Options Guru • Tue, May 14 • 112 Comments
Belviq's Sales Will Disappoint: Demographics Matter
EnhydrisPECorp • Fri, May 10 • 297 Comments
Recent Noteworthy Institutional 5% Ownership Filings In Healthcare Sector
GuruFundPicks • Thu, May 9 • 5 Comments
Top Small-Cap Biotech Stocks Being Accumulated By Large Fund Managers
GuruFundPicks • Tue, May 7 • 8 Comments
Barron's 500: America's Top Companies Leave One Wishing For A Thicker Wallet
Reasonable Risk • Tue, May 7 • 2 Comments
Arena Falls, Pulls Anti-Obesity Application In Europe
Spencer Osborne • Thu, May 2 • 75 Comments
Arena To Offer Quarterly Results - What Investors Need To Hear
Spencer Osborne • Mon, Apr 29 • 23 Comments
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential
Trade In Mexico • Wed, Apr 24 • 26 Comments
Arena Faces A Convergence Of DEA And European Decisions
Reasonable Risk • Wed, Apr 24 • 103 Comments
Arena: The Belviq Launch And Why The Short Thesis Is Wrong
KLLJ Investments • Sun, Apr 14 • 80 Comments
2 Biotechs With A Strong Risk Of Failure
Equity Options Guru • Sun, Apr 14 • 73 Comments
Is Arena Really Launching A New Product And Expanding Its Pipeline?
Reasonable Risk • Tue, Apr 9 • 51 Comments
Prolor Biotech: Unlimited Upside?
Daniel Lauchheimer • Tue, Apr 9 • 12 Comments
As Arena Pharma Begins To Address Mexican Obesity, All Eyes Are Now On The DEA
Heather Ingrassia • Mon, Apr 8 • 27 Comments
There Is No Conspiracy Against Arena Pharmaceuticals
Mark Broer • Thu, Apr 4 • 39 Comments

Vivus' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8 • 1 Comment
Vivus Management Presents at Roth 25th Annual Conference (Transcript)
Tue, Mar 19
Vivus' Management Presents at Barclays Global Healthcare Conference (Transcript)
Thu, Mar 14 • 2 Comments
Vivus CEO Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Feb 25
VIVUS Management Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Nov 6, 2012
VIVUS Management Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Aug 7, 2012 • 1 Comment
VIVUS CEO Discusses Q3 2010 Results - Earnings Call Transcript
Mon, Nov 8, 2010
VIVUS Inc. Q2 2010 Earnings Call Transcript
Mon, Aug 2, 2010
VIVUS, Inc. Q1 2010 Earnings Call Transcript
Mon, May 3, 2010
VIVUS Inc. Q4 2008 Earnings Call Transcript
Mon, Mar 9, 2009
VIVUS Inc. Q2 2008 Earnings Call Transcript
Mon, Aug 4, 2008
VIVUS Inc. Q1 2008 Earnings Call Transcript
Fri, May 30, 2008
VIVUS Inc. Q4 2007 Earnings Call Transcript
Mon, Mar 24, 2008

VIVUS Announces Scientific Presentations

GlobeNewswire (Wed, 7:00AM)
VIVUS Announces Pricing of Offering of $220 Million of 4.50% Convertible Senior Notes

GlobeNewswire (May 16, 2013)
VIVUS Announces Proposed Offering of Convertible Senior Notes

GlobeNewswire (May 15, 2013)
VIVUS Announces Scientific Presentations

GlobeNewswire (May 14, 2013)
VIVUS Mails Letter to Stockholders Providing Business Update

GlobeNewswire (May 13, 2013)
VIVUS Appoints J. Martin Carroll and Jorge Plutzky, M.D. to Board of Directors

GlobeNewswire (May 13, 2013)
VIVUS Reports First Quarter 2013 Financial Results

GlobeNewswire (May 8, 2013)
VIVUS Announces Richard Fante, Former President U.S. and CEO North America, AstraZeneca, to Serve as Senior Advisor

GlobeNewswire (May 7, 2013)
VIVUS Announces Date of First Quarter 2013 Financial Results and Conference Call

GlobeNewswire (May 1, 2013)
New Guidelines From American Association of Clinical Endocrinologists Recommend Medical Treatment of Obesity

GlobeNewswire (May 1, 2013)
VIVUS Appoints Robert N. Wilson to Board of Directors

GlobeNewswire (Apr 30, 2013)
VIVUS Announces Positive Recommendation From CHMP Supporting Avanafil Approval in Europe

GlobeNewswire (Apr 26, 2013)
VIVUS to Present at Four Upcoming Investor Conferences

GlobeNewswire (Apr 22, 2013)
VIVUS Announces FDA Approval of Qsymia REMS Modification Allowing Access Through Certified Retail Pharmacies

PR Newswire (Apr 16, 2013)
VIVUS Announces $110 Million Synthetic Capped Royalty Financing

GlobeNewswire (Mar 26, 2013)
Analysis In Health Economics Review Concludes Effective Medical Obesity Treatment Could Reduce Medicare Spending

PR Newswire (Mar 25, 2013)
VIVUS Confirms Receipt of Notice of Nomination From First Manhattan Co.

GlobeNewswire (Mar 8, 2013)
VIVUS Launches Mobile App to Help Patients Lose Weight

PR Newswire (Mar 7, 2013)
After-Hours Buzz: PAY, NTRI, PLL & More

at CNBC.com (Mar 5, 2013)
Early Movers: JCP, DELL, NFLX & More

at CNBC.com (Mar 5, 2013)

VVUS vs. ETF Alternatives

Company Description

VIVUS, Inc. is a biopharmaceutical company, incorporated in 1991, dedicated to the development and commercialization of therapeutic products for large underserved markets. Our investigational drugs currently under development could serve the obesity, diabetes and sexual health markets. Our... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 24, 10:51 AM Vivus Pharmaceuticals (VVUS +3.6%) extends yesterday's gains, bringing its two-day run to ~13% as Carl Icahn's former head of health care investments Alex Denner is added to First Manhattan's proposed slate of directors. Denner and First Manhattan, who own some 12% of the outstanding shares between them, are critical of VVUS' handling of Qsymia (I, II), and want to get "the best people behind a great asset," First Manhattan says. SA contributor Brian Wilson thinks any weakness in the business is "unlikely to be reflected in the stock price as short sellers worry about a potential bidding war between activist shareholders and management." Comment! [Healthcare, On the Move]
Thursday, May 16, 12:45 PM Vivus (VVUS -3.3%) slips today after pricing its $220M private placement of convertible senior unsecured notes due May 1, 2020. The notes will bear interest at a fixed annual rate of 4.50%, payable semiannually in arrears on May 1 and November 1 of each year, beginning on November 1, 2013. The net proceeds from the offering are expected to be approximately $213M. Comment! [Healthcare, On the Move]
Wednesday, May 15, 2:06 PM Vivus (VVUS -3%) slips today after earlier announcing an aggregate $200M offering of convertible senior unsecured notes due May 1, 2020. It also intends to grant the initial purchasers a 30-day option to purchase up to an additional $30M. The company plans to use a portion of the net proceeds to pay the cost of a capped call transaction, and the remainder for continued development and commercialization of its products. 2 Comments [Healthcare, On the Move]
Tuesday, May 14, 1:50 PM Vivus (VVUS +1.9%) continues to trade higher this week on hopes the company may partner with Big Pharma to expand access to the obesity drug Qsymia (I, II). Nevertheless, some, like Lazard's Joshua Schimmer, say the reality is that demand for the drug has so far proven tepid and VVUS "needs to find commercial success … or significantly reduce costs in order to slow the current cash outflow" — operating expenses rose 208% Y/Y in Q1. Lazard downgrades the shares to Neutral from Buy. Comment! [Healthcare, On the Move]
Monday, May 13, 8:06 AM Vivus (VVUS) rises 2.6% premarket after sending a "business update" letter to shareholders outlining its progress on expanding access to its obesity drug Qsymia. The company reiterates some of the points made on the CC saying it is in discussions with Big Pharma regarding increasing the product's reach and notes the drug will be available at certified pharmacies by mid-July. Ultimately, VVUS says that with a combination of expanded access and reimbursement, Qsymia can be "a top-selling drug." (PR) 3 Comments [Healthcare, On the Move]
Wednesday, May 8, 1:09 PM Vivus (VVUS +8.2%) pops despite posting a Q1 miss as sales of its weight-loss drug Qsymia came in lighter than analysts' expectations. The company wrote off $5.77M due to expired inventory, making it glaringly apparent that Qsymia's launch isn't going as planned. However, in its call, CEO Leland Wilson commented that the company is beginning discussions with large pharmaceutical companies in order to "significantly expand commercialization efforts." Wilson says VVUS has a target of mid-July to bring Qsymia into retail pharmacies. Read more on its earnings call here: Earnings Call Transcript. Comment! [Healthcare, Earnings, On the Move]
Wednesday, May 8, 9:17 AM Premarket gainers: ALXA +51%. PSE +19%. LEDR +16%. NBG +11%. WFM +8%. EA +6%. PRTS +6%. SFUN +6%. CTSH +5%.
Losers: FIO -22%. VCLK -19%. OCLR -19%. AXLL -9%. CIE -7%. CHRW -7%. SODA -6%. DDD -6%. SYMC -5%. Z -5%. VVUS -5%. Comment! [On the Move]
Wednesday, May 8, 7:39 AM Vivus (VVUS): Q1 EPS of -$0.53 misses by $0.01. Revenue of $4.11M misses by $1.11M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, May 8, 12:05 AM Notable earnings before Wednesday’s open: AOL, ARQL, CTSH, CWH, DTEGY.PK, ENB, EZCH, FSYS, FUN, KRO, LMCA, LSE, MPEL, NAVB, NICE, POZN, SODA, STWD, THI, TTI, VVUS, WEN, WMC Comment! [Earnings]
Tuesday, May 7, 5:30 PM Notable earnings before Wednesday’s open: AOL, ARQL, CTSH, CWH, DTEGY.PK, ENB, EZCH, FSYS, FUN, KRO, LMCA, LSE, MPEL, NAVB, NICE, POZN, SODA, STWD, THI, TTI, VVUS, WEN, WMC Comment! [Earnings]
Tuesday, April 30, 11:21 AM Vivus (VVUS +2.2%) says that Qsymia has been added to Medco's national formulary in a tier-3 position with a prior authorization. According to Leerink Swann, the deal essentially converts Qsymia reimbursement from the non-covered to the covered position, and is potentially more important than the previous deal VVUS inked with Express Scripts. 1 Comment [Healthcare, On the Move]
Friday, April 26, 11:12 AM Medivation (MDVN +0.6%) and Astellas Pharma (ALPMF.PK) say the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the oral androgen receptor inhibitor XTANDI (approved in the U.S.) for adult men with progressed metastatic castration-resistant prostate cancer. Other CHMP news: Pfizer's (PFE -1.1%) arthritis pill Xeljanz is rejected (appeal to come), Roche (RHHBY.OB +0.2%) and Curis' (CRIS +4.5%) Erivedge for basal cell carcinoma gets a recommendation, and Vivus' (VVUS +3.7%) ED drug Spedra gets a positive review. (See also: AVNR and CELG get thumbs up from EU regulators) 1 Comment [Healthcare, On the Move]
Friday, April 19, 8:24 AM Vivus (VVUS) rises 5.4% premarket after saying in an 8K that sales of Qsymia rose 29% in March. The company now reports Qsymia shipments by the calendar month: January 16,733; February 18,417; March 23,812. Comment! [Healthcare, On the Move]
Tuesday, April 16, 2:41 PM Vivus (VVUS +5%) spikes as the FDA approves its amendment and modification to the Risk Evaluation and Mitigation Strategy for Qsymia. The amendment, which was submitted last October, allows Qsymia to be dispensed through certified retail pharmacies in addition to the existing network of certified mail-order pharmacies, which reduces the prescribing burden for physicians and waiting times for patients seeking to initiate therapy. 5 Comments [Healthcare, On the Move]
Tuesday, April 9, 4:13 PM Shares of Vivus (VVUS +3.5%) finish solidly in the green today as investors continue to expect Risk Evaluation and Mitigations Strategy modification for Qsymia. Cowen specutlates that many shorts are covering positions ahead of the decision. As of the end of March, over 26M shares, or 26% of the float, was being held short. Comment! [Healthcare, On the Move]
Thursday, March 28, 5:21 PM Bacteria that live in the gut change after gastric-bypass surgery and may aid in weight loss, according to a recent study. Gastric surgery helps people lose weight by shrinking the size of the stomach and making it tougher to absorb calories, now scientists think it may also adjust gastrointestinal bacteria, contributing to weight loss and raising the possibility for less-drastic obesity treatment. 7 Comments [Healthcare]

phemale60
$VVUS the girl all the guys are fighting over, good or bad? Staying nice&green these past few days; good to be wanted!!
18 hours ago
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

phemale60
$VVUS looks heading in right direction. Slow and steady, building momentum.
Wed, 7:53 AM
Reply (1)

• !Report Abuse
View all 1 replies
phemale60: Still maintaining 79% institutional holding status. Flight to $ARNA not occurring.
Wed, 8:59 AM
• !Report Abuse
Add a reply...

140 characters

phemale60
$WFM $VVUS $DECK $LUX $MPEL $BCS $AMRN When you're hot you're hot!!
May 8, 1:58 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

phemale60
$VVUS is sole player now. $ARNA's Belviq rejected in Europe-- still has chance here?
May 3, 8:42 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

phemale60
$VVUS First Manhattan should get out. Only creating disharmony, stirring dissention. Recent good news degraded by FM hostile takeover -
May 1, 3:53 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

EXPstocktrader
$VVUS has reversed from $10
Apr 28, 7:32 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

phemale60
$AMRN $VVUS hitting the right spot today!
Apr 26, 1:17 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

phemale60
$VVUS What the hay? Flopping on good news!
Apr 19, 3:02 PM
Reply (2)

• !Report Abuse
View all 2 replies
wheelz23: if the market makers want to keep a stock price down...that's what happens
Apr 19, 3:12 PM
• !Report Abuse
phemale60: That's awful. I wanted to buy more at $10- was nearly there when shot back up. Don't like buying more at this price even tho prospects good.
Apr 19, 5:28 PM
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
Fuinhaz Setups for April 19 2013 | $ASML $GOLD $GOOG $MDLZ $MSFT $PSEC $VOD $VRTX $VVUS $ZNGA | SharePlanner http://bit.ly/11nYSVZ
Apr 19, 9:20 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Day Trader001
$VVUS momentum rising on good news even though First Manhattan Co. that holds 9.1% of Vivus outstanding stock,
Apr 17, 11:11 AM
Reply (2)

• !Report Abuse
View all 2 replies
Day Trader001: said last week that the company's entry into retail pharmacies was necessary but not sufficient for Qsymia's success!
Apr 17, 11:11 AM
• !Report Abuse
Day Trader001: This could mean $ARNA will also be on shelves very soon without the shareholder negativity.
Apr 17, 11:12 AM
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

phemale60
$VVUS looks heading in right direction. Slow and steady, building momentum.
Wed, 7:53 AM
Reply (1)

• !Report Abuse
View all 1 replies
phemale60: Still maintaining 79% institutional holding status. Flight to $ARNA not occurring.
Wed, 8:59 AM
• !Report Abuse
Add a reply...

140 characters

phemale60
$VVUS What the hay? Flopping on good news!
Apr 19, 3:02 PM
Reply (2)

• !Report Abuse
View all 2 replies
wheelz23: if the market makers want to keep a stock price down...that's what happens
Apr 19, 3:12 PM
• !Report Abuse
phemale60: That's awful. I wanted to buy more at $10- was nearly there when shot back up. Don't like buying more at this price even tho prospects good.
Apr 19, 5:28 PM
• !Report Abuse
Add a reply...

140 characters

Day Trader001
$VVUS momentum rising on good news even though First Manhattan Co. that holds 9.1% of Vivus outstanding stock,
Apr 17, 11:11 AM
Reply (2)

• !Report Abuse
View all 2 replies
Day Trader001: said last week that the company's entry into retail pharmacies was necessary but not sufficient for Qsymia's success!
Apr 17, 11:11 AM
• !Report Abuse
Day Trader001: This could mean $ARNA will also be on shelves very soon without the shareholder negativity.
Apr 17, 11:12 AM
• !Report Abuse
Add a reply...

140 characters

phemale60
$VVUS up near 6% while $ARNA frozen!? What's the story? (not that I'm sad about it). Me and $VVUS go way back !!
Apr 9, 1:55 PM
Reply (4)

• !Report Abuse
View all 4 replies
Eagle Equities: REMS anticipation.
Apr 10, 3:35 PM
• !Report Abuse
phemale60: Yes. Knew it had to be coming. I like it!
Apr 10, 3:57 PM
• !Report Abuse
Add a reply...

140 characters

Red Acre Investments
Sent out Red Acre's weekly review last night $ZIOP, $RPRX, $AMRN, $VVUS, $APPA, $UTHR, $THLD signup at http://www.redacre.com to get it.
Mar 29, 5:26 AM
Reply (3)

• !Report Abuse
View all 3 replies
Red Acre Investments: Thx for the kind words - Happy Easter to you as well.
Mar 29, 5:18 PM
• !Report Abuse
yourmama6799: Rashar for President!!!
Mar 29, 6:43 PM
• !Report Abuse
Add a reply...

140 characters

phemale60
$VVUS loan looks good to me; non dilutive so why the dip? http://yhoo.it/YcMqJW
Mar 26, 10:47 AM
Reply (9)

• !Report Abuse
View all 9 replies
phemale60: I had it since 2009 but was on a cruise when FDA approved, so held when at $31 - should've sold, went down so fast; sold at fraction.
Mar 27, 8:30 PM
• !Report Abuse
phemale60: Now have at $13- been buying on dips near $10- but in red. Not for long tho. Need to be approved for retail pharmacies, then off it will go
Mar 27, 8:35 PM
• !Report Abuse
Add a reply...

140 characters

phemale60
$VVUS coming back from dead -- AGAIN! The horse is nose to nose and moving ahead of the pack! Will win -- just watch!
Mar 6, 3:25 PM
Reply (2)

• !Report Abuse
View all 2 replies
DaLatin: Use the crop !
Mar 6, 3:31 PM
• !Report Abuse
phemale60: LOL, I will -- I do!
Mar 6, 3:36 PM
• !Report Abuse
Add a reply...

140 characters

Husky Financial
good morning! UVXY outperforming TVIX and VVUS is crushing it this morning.. CEO of the latter will be on CNBC halftime report at noon today
2/27/12
Reply (19)

• !Report Abuse
View all 19 replies
johnnyBuz: Silly me bought in early morning at $5.87 with 100% of portfolio
2/27/12
• !Report Abuse
goldozone: $TVIX on the move up
Mar 1, 3:16 PM
• !Report Abuse
Add a reply...

140 characters

Day Trader001
Recognia has detected a "Continuation Wedge (Bearish)" chart pattern formed on $VVUS
Jan 18, 4:03 PM
Reply (3)

• !Report Abuse
View all 3 replies
Day Trader001: The pattern formed over 29 days which is roughly the period of time in which the target price range may be achieved.
Jan 18, 4:03 PM
• !Report Abuse
Day Trader001: This would be a hard drop if the chart pattern holds! "Back to the Raspberry Ultra Drops"
Jan 18, 4:04 PM
• !Report Abuse
Add a reply...

140 characters

Ocean Man
Bought $ARNA at $9.10 as a sympathy play on $VVUS up 9% and short-squeezing.
Jan 7, 9:32 AM
Reply (4)

• !Report Abuse
View all 4 replies
FortSumter: Anybody tuning in to the Biggest Loser last night could easily see the products potential. Haha.
Jan 7, 9:58 AM
• !Report Abuse
Rancodemayor: VVUS too unstable for investors.
Jan 7, 6:07 PM
• !Report Abuse
Add a reply...

140 characters

EXPstocktrader
$VVUS from November article at $10....HAHA
Jan 7, 10:01 AM
Reply (7)

• !Report Abuse
View all 7 replies
EXPstocktrader: Smoked the shorts!
Jan 7, 10:53 AM
• !Report Abuse
phemale60: I don't short, but $VVUS $BCS $MPEL sure helping me on this lousy market day! Grandly!
Jan 7, 11:19 AM
• !Report Abuse
Add a reply...

140 characters

phemale60
$VVUS climbing on $ARNA's DEA scheduling? Go figure.
12/19/12
Reply (2)

• !Report Abuse
View all 2 replies
realornot: no complaint but yes, $VVUS is stealing our scripts! I want my X-tra %!
12/19/12
• !Report Abuse
phemale60: realornot: your day will come -- again -- always does. I think we're both in on the ground floor of something big (no pun intended)!
12/19/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Novo Nordisk ($NVO) "is testing higher dosages [of its drugs] for use in obesity." Bad news for $ARNA & $VVUS http://bit.ly/VLBRb5
12/17/12
Reply (9)

• !Report Abuse
View all 9 replies
1980XLS-2.0: $WTW Seasonal Play. New year's resolution, after holiday binge.
12/17/12
• !Report Abuse
Chemist357: To take a pill or inject yourself...I think Novo nordisk would have a long way to go. Only purpose extend patent life...
12/17/12
• !Report Abuse
Add a reply...

140 characters

phemale60
$VVUS acting like it ought to today! taking time to claim its place as most worth it do. Digging in for the long haul.
12/17/12
Reply (2)

• !Report Abuse
View all 2 replies
Weight Issue: Analysts at Bloomberg Industries noted that Qsymia prescriptions gained 46% week-over-week, citing data from Symphony Health Solutions.
12/17/12
• !Report Abuse
phemale60: good news!! just saw it via Reuters http://reut.rs/VM4vc4
12/17/12
• !Report Abuse
Add a reply...

140 characters

phemale60
Even though lost a bundle on VVUS today, I'm ecstatic Barack Obama re-elected. Some things more important than $$ -- yes.
11/7/12
Reply (47)

• !Report Abuse
View all 47 replies
phemale60: Kept interest rates low for 4 years-can't be all bad. During extraordinary times must take extraordinary actions. Going to be late for work!
12/4/12
• !Report Abuse
ralphey: Phemale how can you work your a democrat !!! Too funny
12/5/12
• !Report Abuse
Add a reply...

140 characters

VVUS Vivus, Inc.

VVUS

Vivus, Inc.